CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.
BACKGROUND
Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is unclear. For example, when to initiate highly active antiretroviral therapy (HAART) during HIV-1 infection remains a clinical dilemma. This decision relies heavily on assessing AIDS risk based on the CD4+ T cell count and plasma viral load. However, the trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk.


RESULTS
In a prospective, single-site, ethnically-mixed cohort of 1,132 HIV-positive subjects, we determined the AIDS risk conveyed by the laboratory and genetic markers separately and in combination. Subjects were assigned to a low, moderate or high genetic risk group (GRG) based on variations in CCL3L1 and CCR5. The predictive value of the CCL3L1-CCR5 GRGs, as estimated by likelihood ratios, was equivalent to that of the laboratory markers. GRG status also predicted AIDS development when the laboratory markers conveyed a contrary risk. Additionally, in two separate and large groups of HIV+ subjects from a natural history cohort, the results from additive risk-scoring systems and classification and regression tree (CART) analysis revealed that the laboratory and CCL3L1-CCR5 genetic markers together provided more prognostic information than either marker alone. Furthermore, GRGs independently predicted the time interval from seroconversion to CD4+ cell count thresholds used to guide HAART initiation.


CONCLUSIONS
The combination of the laboratory and genetic markers captures a broader spectrum of AIDS risk than either marker alone. By tracking a unique aspect of AIDS risk distinct from that captured by the laboratory parameters, CCL3L1-CCR5 genotypes may have utility in HIV clinical management. These findings illustrate how genomic information might be applied to achieve practical benefits of personalized medicine.
Kulkarni
Hemant
H
Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System, San Antonio, Texas, United States of America.
Agan
Brian K
BK
Marconi
Vincent C
VC
O'Connell
Robert J
RJ
Camargo
Jose F
JF
He
Weijing
W
Delmar
Judith
J
Phelps
Kenneth R
KR
Crawford
George
G
Clark
Robert A
RA
Dolan
Matthew J
MJ
Ahuja
Sunil K
SK
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000235:genetics*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D019742:Chemokines, CC / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000175:diagnosis / Q000235:genetics*; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D016013:Likelihood Functions; D008297:Male; D011446:Prospective Studies; D019713:Receptors, CCR5 / Q000235:genetics*; D012306:Risk
C492767:CCL3L1 protein, human; D019742:Chemokines, CC; D019713:Receptors, CCR5
Nat Genet. 2004 Jun;36(6):565-74
15167933
Lancet. 1998 Sep 12;352(9131):866-70
9742978
J Immunol. 2000 Oct 15;165(8):4388-96
11035076
Stat Med. 2004 Jan 30;23(2):271-83
14716728
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15590-5
12434015
Curr Opin HIV AIDS. 2008 May;3(3):342-8
19372988
JAMA. 2006 Aug 16;296(7):815-26
16905787
J Infect Dis. 1994 Apr;169(4):893-7
7907646
AIDS. 2001 Sep 7;15(13):1627-34
11546936
JAMA. 1999 Aug 25;282(8):734
10463706
J Infect Dis. 1998 Oct;178(4):1024-9
9806030
Nat Immunol. 2001 Feb;2(2):102-7
11175801
Nat Immunol. 2007 Dec;8(12):1324-36
17952079
Eur J Immunol. 2002 Oct;32(10):3016-26
12355456
Ann Emerg Med. 1998 Mar;31(3):391-7
9506499
Eur J Emerg Med. 2002 Jun;9(2):115-21
12131632
Clin Infect Dis. 2005 Aug 1;41(3):361-72
16007534
Clin Immunol. 2003 Sep;108(3):234-40
14499246
Ann Intern Med. 1997 Jun 15;126(12):946-54
9182471
Curr Opin HIV AIDS. 2008 Jan;3(1):28-35
19372941
HIV Med. 2003 Jul;4(3):255-62
12859325
J Immunol. 1997 May 1;158(9):4129-36
9126972
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204
11320252
Clin Infect Dis. 2007 Feb 1;44(3):441-6
17205456
MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55
12027060
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15006-10
14657379
Annu Rev Med. 2003;54:535-51
12525683
Nat Med. 2005 Nov;11(11):1180-7
16208318
Blood. 2003 Feb 1;101(3):807-14
12393512
J Virol. 2005 May;79(9):5625-31
15827177
Annu Rev Immunol. 2004;22:891-928
15032599
J Infect Dis. 2001 Jun 1;183(11):1574-85
11335892
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13795-800
12374865
Clin Infect Dis. 2004 Dec 1;39(11):1699-704
15578373
Science. 2005 Mar 4;307(5714):1434-40
15637236
Immunogenetics. 2007 Oct;59(10):793-8
17874089
JAMA. 2006 Sep 27;296(12):1498-506
17003398
AIDS. 2000 May 5;14(7):821-6
10839590
Science. 1996 Sep 27;273(5283):1856-62
8791590
AIDS. 2006 Sep 11;20(14):1879-83
16954729
Eur J Immunol. 2000 Jul;30(7):2048-55
10940894
Immunity. 2007 Sep;27(3):406-16
17892849
Mol Med. 1997 Jan;3(1):23-36
9132277
Nat Immunol. 2006 Oct;7(10):1101-8
16964261
Adv Genet. 2001;42:273-86
11037327
Science. 2007 Apr 13;316(5822):222-34
17431167
Ann Intern Med. 2000 Sep 19;133(6):401-10
10975957
J Infect Dis. 2006 Sep 1;194(5):633-41
16897662
J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):168-75
11404539
J Infect Dis. 2008 Mar 1;197(5):721-7
18266604
Nature. 2006 Apr 13;440(7086):890-5
16612374
Virology. 2007 Aug 1;364(2):281-90
17428518
J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):114-6
14501804
J Infect Dis. 2002 Apr 15;185(8):1055-61
11930315
Ann Behav Med. 2003 Dec;26(3):172-81
14644693
JAMA. 2004 Jul 14;292(2):251-65
15249575
Nat Med. 2008 Apr;14(4):413-20
18376407
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):245-54
18360285
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12004-9
10518566
Virology. 2004 Mar 1;320(1):75-84
15003864
J Clin Invest. 1999 Aug;104(4):R1-5
10449444
Annu Rev Immunol. 2003;21:265-304
12524385
J Infect Dis. 2005 Feb 1;191 Suppl 1:S68-77
15630678
J Virol. 2005 Sep;79(18):11677-84
16140745
AIDS. 1998 Oct 1;12(14):1823-32
9792383
AIDS. 2006 Jul 13;20(11):1531-8
16847408
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):263-71
18391751
J Immunol. 1996 Mar 15;156(6):2095-2103
8690897
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):377-8
17079996
AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1123-33
10954887
J Infect Dis. 2000 Mar;181(3):927-32
10720514
Nat Immunol. 2005 May;6(5):465-71
15821738
J Virol. 2000 Mar;74(6):2584-93
10684272
Clin Infect Dis. 2004 Dec 1;39(11):1705-8
15578374
AIDS. 2002 Sep 27;16(14):1859-66
12351945
AIDS. 2003 Sep 5;17(13):1907-15
12960823
J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):192-9
9949307
AIDS. 2007 Aug 20;21(13):1753-61
17690574
Clin Breast Cancer. 2003 Aug;4(3):203-9
14499014
J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1248-57
7901383
J Biol Chem. 2000 Jun 23;275(25):18946-61
10747879
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93
16249702
J Gen Virol. 2006 Jul;87(Pt 7):2055-2065
16760409
Science. 1998 Dec 4;282(5395):1907-11
9836644
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8401-6
12815099
FEBS Lett. 1999 Aug 27;457(2):219-22
10471782
Ann Allergy. 1984 Feb;52(2):75-82
6696298
J Infect Dis. 1995 Jul;172(1):79-87
7797948